Search results
Results from the WOW.Com Content Network
The forced expression of oncogenic Ras in cultured human MCF-10A breast cancer cells markedly up-regulates BLT2 receptors and this up-regulation appears essential for the epithelial–mesenchymal transition-promoting ability of transforming growth factor beta in these cells; BLT2 receptors in these cells appear to stimulate the production of ...
"Translational control of TWIST1 expression in MCF-10A cell lines recapitulating breast cancer progression". Oncogene. 31 ...
The decoction of aerial parts of F. leucopyrus shows cytotoxic effects on breast cancer cells, particularly Her2 negative cells (MCF-7 and MDA-MB-231), compared to Her2 positive (SKBR-3) and non-cancerous cells (MCF-10A). This supports its traditional use for its anticancer properties.
The miR-200 family (miR-200a, miR-200b, miR-200c, miR-141 and miR-429) and miR-205 are frequently silenced in advanced cancer. Studies has shown that—by targeting the transcriptional repressors of E-cadherin , ZEB1 and ZEB2 miR-205 is involved in epithelial to mesenchymal transition (EMT) and tumor invasion.
During formation of a cancer there is an average reduction of the number of methylated cytosines of about 5% to 20%, [7] or about 840,00 to 3.4 million demethylations of CpG sites. DNMT1 methylates CpGs on hemi-methylated DNA during DNA replication. Thus, when a DNA strand has a methylated CpG, and the newly replicated strand during semi ...
MCF-7 Cells. MCF-7 is a breast cancer cell line isolated in 1970 from a 69-year-old White woman. [1] MCF-7 is the acronym of Michigan Cancer Foundation-7, referring to the institute in Detroit where the cell line was established in 1973 by Herbert Soule and co-workers. [2]
When one of the proteins in the pathway is mutated, it can become stuck in the "on" or "off" position, a necessary step in the development of many cancers. In fact, components of the MAPK/ERK pathway were first discovered in cancer cells, and drugs that reverse the "on" or "off" switch are being investigated as cancer treatments. [1]
The term "induction regimen" refers to a chemotherapy regimen used for the initial treatment of a disease. A " maintenance regimen " refers to the ongoing use of chemotherapy to reduce the chances of a cancer recurring or to prevent an existing cancer from continuing to grow.